Exelixis
EXEL
#1694
Rank
A$17.97 B
Marketcap
A$66.78
Share price
-0.02%
Change (1 day)
19.52%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): A$1.35 Billion

According to Exelixis's latest financial reports the company's current earnings are A$2.28 Billion. In 2024 the company made an earning of A$1.02 Billion, an increase over its 2023 earnings that were of A$0.38 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$1.35 B32.4%
2024 A$1.02 B164.69%
2023 A$0.38 B9.89%
2022 A$0.35 B-20.33%
2021 A$0.44 B124.82%
2020 A$0.19 B-67.14%
2019 A$0.59 B-11.94%
2018 A$0.68 B185.09%
2017 A$0.23 B-325.82%
2016 -A$0.11 Billion-58.12%
2015 -A$0.26 Billion-37.61%
2014 -A$0.41 Billion9.75%
2013 -A$0.37 Billion65.96%
2012 -A$0.23 Billion-291.63%
2011 A$0.11 B-195.59%
2010 -A$0.13 Billion-42.17%
2009 -A$0.21 Billion-18.98%
2008 -A$0.26 Billion-6.99%
2007 -A$0.28 Billion46.3%
2006 -A$0.2 Billion33.25%
2005 -A$0.15 Billion-30.92%
2004 -A$0.21 Billion44.29%
2003 -A$0.15 Billion12.86%
2002 -A$0.13 Billion22.79%
2001 -A$0.11 Billion60.14%
2000 -A$64.53 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
A$14.03 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
A$13.70 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$34.76 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$12.09 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$12.41 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
A$48.77 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$17.84 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-A$49.02 Million-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-A$43.72 Million-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA